The purpose of this study is to assess the safety and efficacy of upadacitinib compared with placebo (fake drug) for the treatment of adults and adolescents with moderate to
severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy.
There are 18 clinic visits over 2 years.
Criteria:Eligible subjects will be individuals who are at least 18 years of age at
Screening with a diagnosis of HS for at least 6 months prior to Baseline and have failed to respond to or are intolerant of anti-TNF therapy
and/or 1 approved non-anti-TNF biologic therapy for HS. Subjects will have moderate to severe HS, defined at Baseline as:
• total AN count of ≥ 5
• the presence of HS lesions in at least 2 distinct anatomic
areas
• at least 1 anatomic area of HS involvement characterized as
Hurley Stage II or higher
• draining fistula count of ≤ 20